Skip to main content
Armata Pharmaceuticals, Inc. logo

Armata Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ARMP ISIN · US04216R1023 LEI · 549300QM1VCWH8KT0S21 US Manufacturing
Open in API
Filings indexed 1,011 across all filing types
Latest filing 2009-03-31 Proxy Solicitation & In…
Country US United States of America
Listing US ARMP

About Armata Pharmaceuticals, Inc.

https://www.armatapharma.com/

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat the global threat of antibiotic-resistant infections. The company's core focus is on creating precisely targeted, high-purity phage-based treatments for serious bacterial infections. This approach aims to provide an effective alternative to conventional antibiotics by eliminating harmful bacteria while preserving the patient's healthy microbiome. Armata's pipeline includes product candidates targeting multi-drug resistant pathogens, supported by its in-house cGMP manufacturing facility for clinical and commercial supply.

Recent filings

Filing Released Lang Actions
Proxy Solicitation & Information Statement 2009
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a letter from Targeted Genetics Corporation responding to SEC staff comments regarding their preliminary proxy statement on Schedule 14A. It discusses amendments to the Restated Articles of Incorporation to increase authorized shares of common stock and details about potential issuance plans. The document references Schedule 14A filings and proxy statements, which are materials related to shareholder voting and corporate governance matters. It is not a financial report, earnings release, or audit report. The content is focused on proxy solicitation and information for shareholders to vote on corporate matters, specifically the increase in authorized shares. Therefore, the document fits the category of Proxy Solicitation & Information Statement (PSI). The document length is over 10,000 characters and contains detailed responses and revised proxy statement excerpts, confirming it is the proxy solicitation material itself, not just an announcement or a brief notice.
2009-03-31 English
Regulatory Filings 2009
Regulatory Filings
2009-03-30 English
SCHEDULE 13G HOLDINGS REPORT
Major Shareholding Notification
2009-03-30 English
PRELIMINARY PROXY STATEMENT
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Preliminary Proxy Statement filed under Schedule 14A with the SEC, related to the 2009 Annual Meeting of Shareholders of Targeted Genetics Corporation. It includes detailed information about proposals to be voted on, such as election of directors, amendments to articles of incorporation, stock incentive plan changes, and ratification of the independent auditor. The document is clearly a proxy solicitation material intended to inform shareholders and solicit their votes for the annual meeting. It is not the actual voting results, nor is it a report of financial results or management discussion. It is not a report publication announcement or a brief notice but a full proxy statement. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI).
2009-03-23 English
8-K FOR GOODWILL IMPAIRMENT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on a goodwill impairment charge and the resulting potential delisting from NASDAQ due to noncompliance with listing requirements. It is not a full annual or quarterly report, nor is it a presentation or earnings release. It is a regulatory announcement of a material event affecting the company. The document length is 3905 characters, which is relatively short and consistent with an 8-K filing. Therefore, the best classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories like delisting announcement (DLST) because it only anticipates possible delisting but does not officially announce it yet.
2009-03-20 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or corporate changes. The content describes the entry into and termination of material definitive agreements between Targeted Genetics Corporation and Celladon Corporation, specifically license and manufacturing agreements. There are no financial statements or detailed financial performance data presented, nor is this a transcript, presentation, or annual/interim report. The document is an announcement of significant corporate agreements and changes, fitting the category of a Regulatory Filing (RNS) as it does not fit more specific categories like M&A or Capital Update. The length (7,717 characters) and detailed description of agreements support this classification rather than a brief announcement or a full report.
2009-03-03 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.